Intravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer
- Choose Your Location
- 855-888-7701
Office Hours
What is intravesical therapy?
Intravesical therapy involves delivering medication directly into the bladder through a thin catheter, allowing high concentrations of treatment agents to act on the bladder lining without significantly entering the bloodstream. It is most used after a transurethral resection of a bladder tumor (TURBT) to treat or prevent the recurrence of non-muscle-invasive bladder cancer (NMIBC).
There are two primary types:
- Intravesical chemotherapy uses agents like mitomycin C or gemcitabine to kill remaining cancer cells and lower the chance of early recurrence.
- Intravesical immunotherapy (i.e.BCG and others) stimulate the immune system to recognize and attack bladder cancer cells.
Who is a candidate for intravesical therapy?
Your urologist will evaluate your tumor stage, grade, and recurrence history to determine whether intravesical therapy is appropriate for you. It is typically recommended for patients with:
- Non-muscle-invasive bladder cancer (stages Ta, T1, or carcinoma in situ)
- Intermediate or high-risk NMIBC following TURBT
- Recurrent low-grade tumors that do not warrant more aggressive intervention
- Carcinoma in situ (CIS), which responds well to intravesical therapy
Muscle-invasive bladder cancer generally requires a different treatment approach, such as radical surgery, systemic chemotherapy and/or radiation.
Who is a candidate for intravesical therapy?
Your urologist will evaluate your tumor stage, grade, and recurrence history to determine whether intravesical therapy is appropriate for you. It is typically recommended for patients with:
- Non-muscle-invasive bladder cancer (stages Ta, T1, or carcinoma in situ)
- Intermediate or high-risk NMIBC following TURBT
- Recurrent low-grade tumors that do not warrant more aggressive intervention
- Carcinoma in situ (CIS), which responds well to intravesical therapy
What happens during an intravesical therapy session?
Each treatment session is performed in the clinic and typically takes up to an hour. Here is what to expect:
- You will be asked to limit fluid intake for a few hours beforehand to reduce urine production during the procedure.
- A nurse or urologist passes a thin catheter into the bladder through the urethra.
- The medication is slowly instilled into the bladder through the catheter.
- You will hold the medication in your bladder for a defined dwell time, typically 1 to 2 hours.
- The catheter is removed, or you are asked to void to drain the medication.
- You may return to normal activity shortly after, though you will receive specific instructions about flushing the medication safely.
What are the potential side effects?
Common side effects
- Urinary urgency or frequency
- Burning or irritation during urination
- Blood in the urine (hematuria)
- Mild bladder cramping
- Flu-like symptoms after BCG (fatigue, low-grade fever)
Less common concerns
- BCG-related systemic infection (rare but serious)
- Bladder contracture with prolonged therapy
- Skin rash or allergic reaction to chemotherapy agents
- Urinary tract infection
Contact your care team promptly if you develop a fever above 101.5 degrees F, significant pain, or symptoms that do not resolve within 48 hours after treatment.
How effective is intravesical BCG therapy?
BCG is very effective intravesical treatment for high-risk non-muscle-invasive bladder cancer. Its benefits include:
- Reducing the risk of tumor recurrence by approximately 30 to 40 percent compared to TURBT alone
- Lowering the risk of disease progression to muscle-invasive bladder cancer
- Achieving complete response in 70 to 75 percent of patients with carcinoma in situ
- Preserving the bladder, avoiding or delaying the need for radical cystectomy
Maintenance BCG therapy, administered over 1 to 3 years, has been shown to provide superior long-term protection compared to induction therapy alone in intermediate and high-risk patients.
Surveillance after intravesical therapy
Regular monitoring is essential even after successful treatment, as bladder cancer has a high recurrence rate. Your surveillance plan will typically include:
- Cystoscopy every 3 months for the first 2 years following treatment
- Urine cytology at each surveillance visit to check for abnormal cells
- Upper tract imaging (CT urogram) at regular intervals, especially in high-risk patients
- Adjusted intervals to every 6 months and then annually based on your recurrence risk and pathology results
Adhering to your surveillance schedule is one of the most important factors in achieving the best long-term outcomes.
Ready to discuss your treatment plan?
Our urologic oncology team will work with you to determine the right approach for your diagnosis and goals. Schedule your appointment today!